Michiel S. van der Heijden

Author

Also Known As

Antoine G. van der Heijden, Heijden, Michiel S, M. S. van der Heijden, M.S. Van Der Heijden, M.S. Van der Heijden, M.S. van der Heijden, MICHIEL S. VAN DER HEIJDEN, Michiel S. van der Heijden, Michiel (S.) Van der Heijden, Michiel S Van Der Heijden

340

Publications

25.7K

Citations

H-Index

Concepts

All Affiliations

The Netherlands Cancer Institute Oncode Institute Queen Mary University of London Institut Gustave Roussy Erasmus MC Cancer Institute

About

Michiel S. van der Heijden is an author at The Netherlands Cancer Institute specializing in medicine, oncology, and urology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	39	56	20.1K
2	Cell Biology	6	6	6.3K
3	Health Sciences	2	2	105
4	Engineering	1	1	44
5	Cellular Physiology	1	1	129

Michiel S. van der Heijden

104

Publications

24.1K

Citations

H-Index

Page 1

	Year	Citations
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells Sanjeev Mariathasan, Shannon J. Turley, Dorothee Nickles, Nature Tumor BiologyCancer ImmunosurveillanceTumour ResponsePd-l1 BlockadeT Cells	2018	5.2K
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial Jonathan E. Rosenberg, Jean Hoffman‐Censits, Tom Powles, The Lancet UrologyMetastatic Urothelial CarcinomaGenitourinary CancerMedicineImmune Checkpoint Inhibitor	2016	3.7K
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial Arjun Vasant Balar, Matthew D. Galsky, Jonathan E. Rosenberg, The Lancet UrologyGenitourinary CancerMedicineFirst-line TreatmentCancer Treatment	2016	2.2K
Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial Thomas Powles, Ignacio Durán, Michiel S. van der Heijden, The Lancet UrologyMetastatic Urothelial CarcinomaGenitourinary CancerMedicineCancer Treatment	2017	1.4K
Enhanced detection of circulating tumor DNA by fragment size analysis Florent Moulière, Dineika Chandrananda, Anna Piskorz, Science Translational Medicine	2018	1K
Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy Roland Seiler, H.A.D.M. Ashab, Nicholas Erho, European Urology UrologyMolecular SubtypesGenitourinary CancerTumor HeterogeneityMedicine	2017	775
Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer Thomas Powles, Begoña P. Valderrama, Shilpa Gupta, New England Journal of Medicine	2024	764
Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial Thomas Powles, Mark Kockx, Alejo Rodríguez‐Vida, Nature Medicine UrologyBiomarker AnalysisGenitourinary CancerMedicineCancer Treatment	2019	555
Mutational Analysis of the Tyrosine Phosphatome in Colorectal Cancers Zhenghe Wang, Dong Shen, D. Williams Parsons, Science Tyrosine PhosphorylationTyrosine PhosphatomeTyrosine Phosphatase GeneCell SignalingMedicine	2004	520
Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up Tom Powles, Joaquim Bellmunt, Éva Compérat, Annals of Oncology UrologySurgical OncologyGenitourinary CancerMedicineCancer Management	2021	492

Page 1